trending Market Intelligence /marketintelligence/en/news-insights/trending/yysl3klfe0l4zvo-4aqtdw2 content esgSubNav
In This List

Destiny Pharma chairman to step down; replacement named

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Destiny Pharma chairman to step down; replacement named

Destiny Pharma PLC said Nigel Rudd is stepping down as chairman and a member of its board Dec. 31.

Rudd will be replaced by Nick Rodgers, a nonexecutive director of Destiny Pharma, in the chairman role.

Brighton, U.K.-based Destiny Pharma develops and sells medicines for infectious diseases.